SAGE Therapeutics Inc (NASDAQ:SAGE) Director Steven M. Paul sold 58,139 shares of SAGE Therapeutics stock in a transaction dated Tuesday, March 6th. The shares were sold at an average price of $172.00, for a total transaction of $9,999,908.00. Following the completion of the sale, the director now directly owns 632,712 shares in the company, valued at approximately $108,826,464. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of SAGE Therapeutics Inc (NASDAQ:SAGE) opened at $177.75 on Friday. SAGE Therapeutics Inc has a 52 week low of $59.57 and a 52 week high of $195.97. The company has a market cap of $7,650.00, a PE ratio of -25.07 and a beta of 3.07.
SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported ($1.75) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.98) by $0.23. During the same quarter last year, the firm posted ($1.50) earnings per share. research analysts expect that SAGE Therapeutics Inc will post -8.2 earnings per share for the current fiscal year.
Several hedge funds and other institutional investors have recently made changes to their positions in SAGE. Oppenheimer Asset Management Inc. lifted its stake in shares of SAGE Therapeutics by 412.9% in the third quarter. Oppenheimer Asset Management Inc. now owns 1,944 shares of the biopharmaceutical company’s stock valued at $122,000 after purchasing an additional 1,565 shares during the period. Bessemer Group Inc. acquired a new stake in shares of SAGE Therapeutics in the third quarter valued at about $141,000. Fortaleza Asset Management Inc. acquired a new stake in shares of SAGE Therapeutics in the fourth quarter valued at about $167,000. First Mercantile Trust Co. acquired a new stake in shares of SAGE Therapeutics in the fourth quarter valued at about $169,000. Finally, Envestnet Asset Management Inc. lifted its stake in shares of SAGE Therapeutics by 70.7% in the third quarter. Envestnet Asset Management Inc. now owns 2,906 shares of the biopharmaceutical company’s stock valued at $182,000 after purchasing an additional 1,204 shares during the period. Hedge funds and other institutional investors own 95.63% of the company’s stock.
SAGE Therapeutics Company Profile
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.